ReviewCancer chemotherapy and pharmacology2025

Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences.

Yangqingqing Zhou et al.PubMed ↗Publisher ↗

No numbers read from the abstract.